ISRG · Company research
Intuitive Surgical Inc. (ISRG): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
56records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Stock Futures Fall Before the Open | Stock futures opened lower as investors await economic data and earnings reports. The housing market continues to struggle with September Housing Starts and Building Permits missing expectations, driven by elevated mortgage rates. GE and GM both beat Q3 earnings estimates, though GM's downward guidance weighed on shares. Netflix, United Airlines, and Intuitive Surgical are set to report earnings today. | View source ↗ | Zacks Investment Research | Oct 20, 2026 | neutral | 0 | 1 |
| Pre-Markets Down, Housing Remains at Recessionary Levels | Stock futures opened lower on October 20, 2026, driven by rising oil prices amid geopolitical tensions in the Strait of Hormuz. September housing data disappointed with starts and permits both declining, reflecting weakness in the real estate market due to elevated mortgage rates. GE and GM beat Q3 earnings expectations, though GM's downward guidance pressured shares. Netflix, United Airlines, and Intuitive Surgical are set to report earnings after market close. | View source ↗ | Zacks Investment Research | Oct 20, 2026 | neutral | 0 | 1 |
| Breakfast News: A One-Line Fix Could Shake Up AI | Amazon released TorchNeuron, an open-source software tool that allows PyTorch code to run on AWS Trainium chips with minimal changes, challenging Nvidia's market dominance. Amazon stock surged 5% on the announcement. Meanwhile, Karooooo's shares fell 8% despite strong subscriber growth due to lower-than-expected earnings and unchanged guidance. Netflix and SpaceX are set to report earnings, with Netflix focusing on ad revenue growth and SpaceX on AI spending efficiency. MercadoLibre continues expanding in Latin America with heavy investments in shipping and payments. | View source ↗ | The Motley Fool | Oct 20, 2026 | neutral | 0.056 | 1 |
| 3 Wall Street Analysts See Intuitive Surgical Hitting $500. Here's the Bull Case. | Three Wall Street analysts have $500 price targets for Intuitive Surgical, citing strong growth in robot-assisted surgery procedures and the rollout of the da Vinci 5 platform. The company benefits from a recurring revenue model through instruments and accessories, with procedures growing 15% year-over-year. However, the stock's high P/E ratio of ~49 leaves limited room for disappointment. | View source ↗ | The Motley Fool | Oct 19, 2026 | bullish | 0.333 | 1 |
| Stryker Enters Soft-Tissue Robotics With $400 Million CMR Deal | Stryker announced a $400 million preferred equity investment in CMR Surgical, gaining exclusive U.S. sales rights for the Versius robotic surgery platform and an option to acquire the company. The deal allows Stryker to expand into soft-tissue robotics, complementing its existing Mako orthopedic platform, while CMR Surgical retains global commercialization rights outside the U.S. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 0.25 | 1 |
| Zacks Investment Ideas feature highlights: Intuitive Surgical | Intuitive Surgical (ISRG), the leader in surgical robotics, has fallen 30% from early 2025 highs but presents a strong buy opportunity with ~40% upside potential. The company demonstrates impressive fundamentals including double-digit earnings and revenue growth, a debt-free balance sheet, and strong free cash flow expansion. ISRG earned a Zacks Rank #2 (Buy) rating and is positioned for a technical breakout ahead of Q3 earnings. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 0.333 | 1 |
| Intuitive Surgical (ISRG) Stock Is Down 25% Year to Date. History Says Patient Investors Get Rewarded. - The Motley Fool | Intuitive Surgical (ISRG) Stock Is Down 25% Year to Date. History Says Patient Investors Get Rewarded. The Motley Fool | View source ↗ | The Motley Fool | Oct 17, 2026 | neutral | 0 | 0.6 |
| Intuitive Surgical (ISRG) Stock Is Down 25% Year to Date. History Says Patient Investors Get Rewarded. - AOL.com | Intuitive Surgical (ISRG) Stock Is Down 25% Year to Date. History Says Patient Investors Get Rewarded. AOL.com | View source ↗ | AOL.com | Oct 17, 2026 | neutral | 0 | 0.6 |
| Forget AI Stocks: Buy Med-Tech Stock ISRG Now for 40% Upside - Zacks Investment Research | Forget AI Stocks: Buy Med-Tech Stock ISRG Now for 40% Upside Zacks Investment Research | View source ↗ | Zacks Investment Research | Oct 16, 2026 | neutral | 0 | 0.6 |
| Forget AI Stocks: Buy Med-Tech Stock ISRG Now for 40% Upside | Intuitive Surgical, the leader in surgical robotics, has fallen 30% from early 2025 highs but is poised for a technical breakout ahead of its Q3 earnings release on October 20. With strong fundamentals including double-digit earnings and revenue growth, a debt-free balance sheet, and ~43% upside potential to all-time highs, the stock earns a Zacks Rank #2 (Buy) rating. The company projects 15% Q3 revenue growth and 17% revenue growth for 2026. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.333 | 1 |
| Forget AI Stocks: Buy Med-Tech Stock ISRG Now for 40% Upside - TradingView | Forget AI Stocks: Buy Med-Tech Stock ISRG Now for 40% Upside TradingView | View source ↗ | TradingView | Oct 16, 2026 | neutral | 0 | 0.6 |
| If You Invested $1000 In Intuitive Surgical Stock 10 Years Ago, You Would Have This Much Today - Benzinga | If You Invested $1000 In Intuitive Surgical Stock 10 Years Ago, You Would Have This Much Today Benzinga | View source ↗ | Benzinga | Oct 16, 2026 | neutral | 0 | 0.6 |
| Inflation Pressures Rise as Services Activity Weakens | Q3 earnings season shows mixed results with early reports tracking modestly below recent quarters. Import prices hit their highest rate since May at +1.1%, signaling persistent inflation concerns. The New York Fed's October Services report plummeted to -20.7, marking the sharpest decline since March. Key earnings this week included Travelers beating expectations with a +29.84% earnings surprise, while regional banks showed modest beats. Major tech and consumer companies including Netflix, Tesla, Meta, and General Motors are set to report next week. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.263 | 1 |
| First Week of Q3 Earnings in the Books | Q3 earnings season shows mixed results with early reports tracking modestly below recent quarters. Import prices rose higher than expected in September (+1.1% vs +0.8% expected), marking the highest rate since May. The NY Fed's October Services report came in significantly below expectations at -20.7 vs -4.1 expected, hitting its lowest level since March. Among earnings reports, Travelers beat estimates by 29.84%, while regional banks Regions Financial, Citizens Financial Group, and M&T Bank also beat earnings expectations. Major tech earnings from Netflix, Tesla, Meta, and others are expected next week. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.263 | 1 |
| First Week of Q3 Earnings in the Books | Q3 earnings season shows mixed results with early reports tracking modestly below recent quarters. Import prices rose higher than expected in September (+1.1% vs +0.8% expected), marking the highest rate since May. The NY Fed's October Services report came in significantly below expectations at -20.7 vs -4.1 expected, hitting its lowest level since March. Among earnings reports, Travelers beat estimates by 29.84%, while regional banks Regions Financial, Citizens Financial Group, and M&T Bank also beat earnings expectations. Major tech earnings from Netflix, Tesla, Meta, and others are expected next week. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.263 | 1 |
| Intuitive Surgical (ISRG) Stock May Be Fairly Valued On New Robotics Competition - Yahoo Finance | Intuitive Surgical (ISRG) Stock May Be Fairly Valued On New Robotics Competition Yahoo Finance | View source ↗ | Yahoo Finance | Oct 16, 2026 | neutral | 0 | 0.6 |
| ISRG Ahead of Q3 Earnings: Can Procedure Growth Sustain Momentum? | Intuitive Surgical (ISRG) is expected to report Q3 2026 earnings on October 20 with EPS projected at $2.61 (up 8.75%) and revenue growth of 15% to $2.88B. While the company benefits from international procedure growth and strong da Vinci 5 demand, it faces headwinds from moderating U.S. procedure growth, China pricing pressures, and higher costs. The stock trades at a premium valuation of 35.87X forward P/E, leaving limited room for disappointment. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | neutral | 0 | 1 |
| ISRG Ahead of Q3 Earnings: Can Procedure Growth Sustain Momentum? | Intuitive Surgical (ISRG) is expected to report Q3 2026 earnings on October 20 with EPS projected at $2.61 (up 8.75%) and revenue growth of 15% to $2.88B. While the company benefits from international procedure growth and strong da Vinci 5 demand, it faces headwinds from moderating U.S. procedure growth, China pricing pressures, and higher costs. The stock trades at a premium valuation of 35.87X forward P/E, leaving limited room for disappointment. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | neutral | 0 | 1 |
| Intuitive Surgical, Inc. (ISRG) Beats Stock Market Upswing: What Investors Need to Know | Intuitive Surgical (ISRG) outperformed the broader market on October 15, 2026, closing up 1.81% and gaining 9.93% over the past month. The company has a Zacks Rank #2 (Buy) rating with expected Q3 EPS growth of 8.75% and full-year earnings growth of 20.27%. However, the stock trades at a premium valuation with a Forward P/E of 39.15 compared to the industry average of 23.25. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| Intuitive Surgical, Inc. (ISRG) Beats Stock Market Upswing: What Investors Need to Know | Intuitive Surgical (ISRG) outperformed the broader market on October 15, 2026, closing up 1.81% and gaining 9.93% over the past month. The company has a Zacks Rank #2 (Buy) rating with expected Q3 EPS growth of 8.75% and full-year earnings growth of 20.27%. However, the stock trades at a premium valuation with a Forward P/E of 39.15 compared to the industry average of 23.25. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| Intuitive Surgical, Inc. (ISRG) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance | Intuitive Surgical, Inc. (ISRG) Beats Stock Market Upswing: What Investors Need to Know Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| ISRG 261016 545.00P (ISRG261016P545000) Stock Options Chain | Quotes & News - Moomoo | ISRG 261016 545.00P (ISRG261016P545000) Stock Options Chain | Quotes & News Moomoo | View source ↗ | Moomoo | Oct 15, 2026 | neutral | 0 | 0.6 |
| ISRG Gains Nearly 12% in a Month: Should You Buy, Hold or Sell? | Intuitive Surgical (ISRG) has gained nearly 12% in a month, outperforming the market ahead of Q3 earnings. The company benefits from strong da Vinci 5 adoption, growing Ion procedures, and expanding international markets. However, slower U.S. procedure growth, GLP-1 drug competition affecting bariatric procedures, and China headwinds pose risks. ISRG trades at a premium 36.04X forward P/E but remains attractive with a Zacks Rank #2 (Buy) rating. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.333 | 1 |
| Intuitive Surgical (ISRG) Stock May Be Near Fair Value Despite Fresh Robotics Competition - Simply Wall Street | Intuitive Surgical (ISRG) Stock May Be Near Fair Value Despite Fresh Robotics Competition Simply Wall Street | View source ↗ | Simply Wall Street | Oct 14, 2026 | neutral | 0 | 0.6 |
| 1,062 shares withheld for taxes as Intuitive Surgical (ISRG) executive converts stock units. - Stock Titan | 1,062 shares withheld for taxes as Intuitive Surgical (ISRG) executive converts stock units. Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| Of Gary Loeb’s vesting shares, 1,296 were withheld for taxes at Intuitive Surgical (ISRG). - Stock Titan | Of Gary Loeb’s vesting shares, 1,296 were withheld for taxes at Intuitive Surgical (ISRG). Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| ISRG Is Expanding Beyond Surgery: Here's Why the GI Opportunity Matters | Intuitive Surgical submitted a next-generation flexible robotic endoscope to the FDA for 510(k) clearance, marking expansion into gastrointestinal care. The platform combines expertise from da Vinci surgical systems and Ion lung biopsy platform but remains in early development with no near-term revenue expected. Success will depend on regulatory approval, clinical evidence, and physician adoption. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| ISRG Is Expanding Beyond Surgery: Here's Why the GI Opportunity Matters | Intuitive Surgical submitted a next-generation flexible robotic endoscope to the FDA for 510(k) clearance, marking expansion into gastrointestinal care. The platform combines expertise from da Vinci surgical systems and Ion lung biopsy platform but remains in early development with no near-term revenue expected. Success will depend on regulatory approval, clinical evidence, and physician adoption. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Intuitive Surgical (ISRG) Upgraded to Buy: Here's Why | Intuitive Surgical (ISRG) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company's consensus estimate for fiscal year 2026 remains at $10.74 per share, with analysts raising estimates by 3.5% over the past three months. The upgrade positions ISRG in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price appreciation driven by improving business fundamentals. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Intuitive Surgical (ISRG) Upgraded to Buy: Here's Why | Intuitive Surgical (ISRG) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company's consensus estimate for fiscal year 2026 remains at $10.74 per share, with analysts raising estimates by 3.5% over the past three months. The upgrade positions ISRG in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price appreciation driven by improving business fundamentals. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Investors Heavily Search Intuitive Surgical, Inc. (ISRG): Here is What You Need to Know | Intuitive Surgical (ISRG) has been heavily searched on Zacks.com and has outperformed the broader market with a +13.2% return over the past month. The company holds a Zacks Rank #2 (Buy) rating based on strong earnings estimate trends, with expected earnings growth of +20.3% for the current fiscal year and +11.6% for the next year. Revenue is projected to grow +16.7% and +12.5% respectively. However, the stock trades at a premium valuation (D grade) compared to peers. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Investors Heavily Search Intuitive Surgical, Inc. (ISRG): Here is What You Need to Know | Intuitive Surgical (ISRG) has been heavily searched on Zacks.com and has outperformed the broader market with a +13.2% return over the past month. The company holds a Zacks Rank #2 (Buy) rating based on strong earnings estimate trends, with expected earnings growth of +20.3% for the current fiscal year and +11.6% for the next year. Revenue is projected to grow +16.7% and +12.5% respectively. However, the stock trades at a premium valuation (D grade) compared to peers. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? | Abbott Laboratories and Intuitive Surgical represent different healthcare investment strategies. Abbott offers diversified operations across diagnostics, nutrition, and medical devices with a conservative 18x forward P/E ratio, $7.4B free cash flow, and 2.49% dividend yield. Intuitive Surgical commands a premium 39x P/E multiple but delivers 21% revenue growth, zero debt, and dominance in robotic-assisted surgery. Both companies project ~13% sales growth for 2026, but Abbott's lower valuation and new Cologuard cancer screening acquisition make it the better buy for long-term value investors. | View source ↗ | The Motley Fool | Oct 12, 2026 | bullish | 0.25 | 1 |
| 4 Healthcare Stocks Worth Owning for the Next Decade | The article recommends four healthcare stocks across two key niches: GLP-1 weight-loss drugs (Eli Lilly and Novo Nordisk) and surgical robotics (Intuitive Surgical and Medtronic). Eli Lilly leads in GLP-1 but faces patent expiration risks, while Novo Nordisk is a turnaround story with attractive valuation. Intuitive Surgical dominates surgical robotics with strong recurring revenue, while Medtronic offers a diversified play with dividend appeal as it launches its Hugo surgical robot. | View source ↗ | The Motley Fool | Oct 12, 2026 | bullish | 0.75 | 1 |
| ISRG 261009 387.50P (ISRG261009P387500) Stock Options Chain | Quotes & News - Moomoo | ISRG 261009 387.50P (ISRG261009P387500) Stock Options Chain | Quotes & News Moomoo | View source ↗ | Moomoo | Oct 10, 2026 | neutral | 0 | 0.6 |
| Intuitive Surgical (ISRG) Shares Just Moved, So What Is Driving Attention Now? - Simply Wall Street | Intuitive Surgical (ISRG) Shares Just Moved, So What Is Driving Attention Now? Simply Wall Street | View source ↗ | Simply Wall Street | Oct 10, 2026 | neutral | 0 | 0.6 |
| Intuitive Surgical, Inc. (ISRG) Exceeds Market Returns: Some Facts to Consider | Intuitive Surgical (ISRG) outperformed the S&P 500 with a +2.06% daily gain, reaching $423.96. The stock has gained 15.24% prior to trading and is expected to report Q3 earnings on October 20, 2026, with forecasted EPS of $2.61 (+8.75% YoY) and revenue of $2.88 billion (+14.98% YoY). However, the stock trades at a premium valuation with a Forward P/E of 38.7 versus the industry average of 22.63, and holds a Zacks Rank of #3 (Hold). | View source ↗ | Zacks Investment Research | Oct 9, 2026 | neutral | 0 | 1 |
| Fund Update: 54,499 INTUITIVE SURGICAL (ISRG) shares added to Douglas Lane & Associates, LLC portfolio - Quiver Quantitative | Fund Update: 54,499 INTUITIVE SURGICAL (ISRG) shares added to Douglas Lane & Associates, LLC portfolio Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 9, 2026 | neutral | 0 | 0.6 |
| ISRG 261009 395.00P (ISRG261009P395000) Stock Options Chain | Quotes & News - Moomoo | ISRG 261009 395.00P (ISRG261009P395000) Stock Options Chain | Quotes & News Moomoo | View source ↗ | Moomoo | Oct 8, 2026 | neutral | 0 | 0.6 |
| Prediction: Johnson & Johnson Will Be a Faster-Growing Company by 2030 Than Most Investors Expect | Johnson & Johnson is positioned for faster growth by 2030 following its separation from its slower-growing consumer health division. The company can now focus investments on its faster-growing biopharma and medtech segments. Key growth drivers include recent drug approvals like ICOTYDE and the FDA-cleared Ottava robotic surgery system, which operates in a market with significant expansion potential. Despite challenges from government price negotiations and talc-related lawsuits, J&J's diversified portfolio and strong dividend history make it an attractive long-term investment. | View source ↗ | The Motley Fool | Oct 8, 2026 | bullish | 0.5 | 1 |
| Prediction: Johnson & Johnson Will Be a Faster-Growing Company by 2030 Than Most Investors Expect | Johnson & Johnson is positioned for faster growth by 2030 following its separation from its slower-growing consumer health division. The company can now focus investments on its faster-growing biopharma and medtech segments. Key growth drivers include recent drug approvals like ICOTYDE and the FDA-cleared Ottava robotic surgery system, which operates in a market with significant expansion potential. Despite challenges from government price negotiations and talc-related lawsuits, J&J's diversified portfolio and strong dividend history make it an attractive long-term investment. | View source ↗ | The Motley Fool | Oct 8, 2026 | bullish | 0.5 | 1 |
| Prediction: Johnson & Johnson Will Be a Faster-Growing Company by 2030 Than Most Investors Expect | Johnson & Johnson is positioned for faster growth by 2030 following its separation from its slower-growing consumer health division. The company can now focus investments on its faster-growing biopharma and medtech segments. Key growth drivers include recent drug approvals like ICOTYDE and the FDA-cleared Ottava robotic surgery system, which operates in a market with significant expansion potential. Despite challenges from government price negotiations and talc-related lawsuits, J&J's diversified portfolio and strong dividend history make it an attractive long-term investment. | View source ↗ | The Motley Fool | Oct 8, 2026 | bullish | 0.5 | 1 |
| Intuitive Surgical Inc. Stock Grades | ISRG - Barron's | Intuitive Surgical Inc. Stock Grades | ISRG Barron's | View source ↗ | Barron's | Oct 8, 2026 | neutral | 0 | 0.6 |
| Intuitive Surgical (NASDAQ:ISRG) Combines Strong Growth With a Constructive Technical Setup - ChartMill | Intuitive Surgical (NASDAQ:ISRG) Combines Strong Growth With a Constructive Technical Setup ChartMill | View source ↗ | ChartMill | Oct 8, 2026 | neutral | 0 | 0.6 |
| Intuitive Surgical, Inc. (ISRG) Gains As Market Dips: What You Should Know | Intuitive Surgical (ISRG) gained 2.41% to $414.52 on October 7, 2026, outperforming a declining market. The stock has surged 15.59% over the past month, significantly outpacing the Medical sector's 4.73% loss. Upcoming earnings on October 20 are expected to show 8.75% EPS growth and 14.98% revenue growth year-over-year. However, the stock carries a Zacks Rank #3 (Hold) rating with a premium Forward P/E of 37.71 versus the industry average of 23.11. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | neutral | 0 | 1 |
| Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise? | Intuitive Surgical's single-port (SP) platform is emerging as a significant growth franchise with 61% year-over-year procedure growth and an installed base of 445 systems. Strong U.S. utilization gains (25% YoY) and expanding stapler adoption (nearly 60% of eligible cases) support the platform's trajectory toward becoming a billion-dollar business. The company is also expanding internationally and through product innovation. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Jim Cramer Has Soured on Intuitive Surgical (ISRG). The Reason is Johnson & Johnson - Yahoo Finance | Jim Cramer Has Soured on Intuitive Surgical (ISRG). The Reason is Johnson & Johnson Yahoo Finance | View source ↗ | Yahoo Finance | Oct 7, 2026 | neutral | 0 | 0.6 |
| What Could Lift ISRG Stock? - Trefis | What Could Lift ISRG Stock? Trefis | View source ↗ | Trefis | Oct 6, 2026 | neutral | 0 | 0.6 |
| Intuitive Surgical: The Multiple Fell, The Story Didn't (NASDAQ:ISRG) - Seeking Alpha | Intuitive Surgical: The Multiple Fell, The Story Didn't (NASDAQ:ISRG) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 6, 2026 | neutral | 0 | 0.6 |
| Zacks Industry Outlook Globus Medical, Intuitive Surgical and Thermo Fisher Scientific | The Medical Instruments industry is experiencing growth driven by generative AI adoption, with the AI-enabled medical devices market projected to expand at 19.9% CAGR through 2034. The industry carries a Zacks Industry Rank #86 (top 35%), though it has underperformed the S&P 500 and broader sector over the past year. Three stocks highlighted for potential outperformance are Globus Medical (Rank #1), Intuitive Surgical (Rank #2), and Thermo Fisher Scientific (Rank #2), all benefiting from AI integration, M&A activity, and strong earnings growth projections. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 1 | 1 |
| Zacks Industry Outlook Globus Medical, Intuitive Surgical and Thermo Fisher Scientific | The Medical Instruments industry is experiencing growth driven by generative AI adoption, with the AI-enabled medical devices market projected to expand at 19.9% CAGR through 2034. The industry carries a Zacks Industry Rank #86 (top 35%), though it has underperformed the S&P 500 and broader sector over the past year. Three stocks highlighted for potential outperformance are Globus Medical (Rank #1), Intuitive Surgical (Rank #2), and Thermo Fisher Scientific (Rank #2), all benefiting from AI integration, M&A activity, and strong earnings growth projections. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 1 | 1 |
| Intuitive Surgical Inc Stock (ISRG) Moved Up by 3.02% on Oct 5: Key Drivers Unveiled - TradingKey | Intuitive Surgical Inc Stock (ISRG) Moved Up by 3.02% on Oct 5: Key Drivers Unveiled TradingKey | View source ↗ | TradingKey | Oct 5, 2026 | neutral | 0 | 0.6 |
| Can ISRG Offset China Weakness With Expansion in India and Japan? | Intuitive Surgical faces headwinds in China due to weak tenders, domestic competition, and pricing pressure, with only two systems placed. However, the company is diversifying growth through strong momentum in India following da Vinci 5 clearance and improved conditions in Japan with new reimbursement policies supporting 25 system placements. International da Vinci procedures grew 20% in Q2, with management maintaining its 2026 procedure growth outlook of 13.5-15.5%. | View source ↗ | Zacks Investment Research | Oct 2, 2026 | bullish | 0.667 | 1 |
| Can ISRG Offset China Weakness With Expansion in India and Japan? | Intuitive Surgical faces headwinds in China due to weak tenders, domestic competition, and pricing pressure, with only two systems placed. However, the company is diversifying growth through strong momentum in India following da Vinci 5 clearance and improved conditions in Japan with new reimbursement policies supporting 25 system placements. International da Vinci procedures grew 20% in Q2, with management maintaining its 2026 procedure growth outlook of 13.5-15.5%. | View source ↗ | Zacks Investment Research | Oct 2, 2026 | bullish | 0.667 | 1 |
| 2 Beaten-Down Stocks to Buy Before They Bounce Back - The Motley Fool | 2 Beaten-Down Stocks to Buy Before They Bounce Back The Motley Fool | View source ↗ | The Motley Fool | Sep 22, 2026 | neutral | 0 | 0.6 |
| How Far Could ISRG Stock Bounce From Here? - Yahoo Finance | How Far Could ISRG Stock Bounce From Here? Yahoo Finance | View source ↗ | Yahoo Finance | Sep 21, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.